--- title: "Korean drugmakers will face a two-sided squeeze: falling returns from generics just as the government pushes them to spend more on R&D." description: "South Korea plans to give companies that meet minimum R&D thresholds preferential drug pricing, while cutting generic reimbursement from about 54% towards 45%. That means the cash flows many manufactu" url: "https://bilby.ai/predictions/p/113/korean-drugmakers-will-face-a-two-sided-squeeze-falling-returns-from-generics-ju" markdown: "https://bilby.ai/predictions/p/113/korean-drugmakers-will-face-a-two-sided-squeeze-falling-returns-from-generics-ju.md" index: "https://bilby.ai/llms.txt" --- > For agents: Bilby answers questions about what governments do, from documents collected at source and checked by research analysts. To ask Bilby yourself, connect to its MCP server at https://pulse.bilby.ai/mcp (setup: https://docs.bilby.ai/developers/mcp-server). Every page on this site is also markdown: add .md to its address, or send Accept: text/markdown. https://bilby.ai/llms.txt lists them all. # Korean drugmakers will face a two-sided squeeze: falling returns from generics just as the government pushes them to spend more on R&D. - **Made:** 21 Sep 2026 - **By:** Owen Bae - **Market:** South Korea - **Outcome:** Unresolved South Korea plans to give companies that meet minimum R&D thresholds preferential drug pricing, while cutting generic reimbursement from about 54% towards 45%. That means the cash flows many manufacturers rely on to fund research will weaken at the same time as the requirements for pricing privileges grow. Firms may respond by selling lower-margin generic lines and redirecting the proceeds into R&D, but without foreign pharmaceutical buyers or other sources of outside capital, many could face several hard years where profits will fall. [Ask Bilby about this prediction](https://pulse.bilby.ai/?prompt=Korean%20drugmakers%20will%20face%20a%20two-sided%20squeeze%3A%20falling%20returns%20from%20generics%20just%20as%20the%20government%20pushes%20them%20to%20spend%20more%20on%20R%26D.) ## Ask Bilby about it Carry the prediction into a question: what has changed since, who decides, and who is exposed. - [What has changed since it was made?](https://pulse.bilby.ai/?prompt=What%20has%20changed%20since%20Bilby%20predicted%20this%3F%20Korean%20drugmakers%20will%20face%20a%20two-sided%20squeeze%3A%20falling%20returns%20from%20generics%20just%20as%20the%20government%20pushes%20them%20to%20spend%20more%20on%20R%26D.) - [Who decides whether it happens?](https://pulse.bilby.ai/?prompt=Who%20decides%20whether%20this%20happens%3F%20Korean%20drugmakers%20will%20face%20a%20two-sided%20squeeze%3A%20falling%20returns%20from%20generics%20just%20as%20the%20government%20pushes%20them%20to%20spend%20more%20on%20R%26D.) - [Who gains and who loses if it does?](https://pulse.bilby.ai/?prompt=Who%20gains%20and%20who%20loses%20if%20this%20happens%3F%20Korean%20drugmakers%20will%20face%20a%20two-sided%20squeeze%3A%20falling%20returns%20from%20generics%20just%20as%20the%20government%20pushes%20them%20to%20spend%20more%20on%20R%26D.) ## More from South Korea 27 predictions on South Korea so far, newest first. - 4 Nov 2026 · [Rhythm Pharmaceuticals is likely to exceed US$750 million in rare-obesity drug sales in 2027, more than double the annual sales pace implied by its third-quarter 2026 results.](https://bilby.ai/predictions/p/203/rhythm-pharmaceuticals-is-likely-to-exceed-us-750-million-in-rare-obesity-drug-s) · Unresolved - 27 Oct 2026 · [Washington’s South Korean advanced memory chipmaker anti-China restrictions will hit Samsung much harder than Beijing.](https://bilby.ai/predictions/p/188/washington-s-south-korean-advanced-memory-chipmaker-anti-china-restrictions-will) · Unresolved - 26 Oct 2026 · [South Korea’s steel market pushes back on China yet harder.](https://bilby.ai/predictions/p/187/south-korea-s-steel-market-pushes-back-on-china-yet-harder) · Unresolved [All 27 from South Korea](https://bilby.ai/predictions/log?tag=south-korea) · Marked true or false when each resolves ## See what we’re seeing next. New predictions in the Asia Daily Take, free every weekday, and in Bilby whenever you have a question. [Get the Asia Daily Take](https://bilby.ai/asia#asia-daily-take) · [Try Bilby](https://pulse.bilby.ai/sign-up)